Sugi Predict

Sugi Predict / Compounds / SCHEMBL208151

SCHEMBL208151

SCHEMBL208151

Nc1ncc(Br)c(Cl)c1[N+](=O)[O-]

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 6/20 0.40
▸ LMNA P02545 5/20 0.40
▸ TSHR P16473 2/20 0.38
▸ MAPT P10636 6/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ MITF O75030 1/20 0.36
▸ PTGER4 P35408 1/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ ALDH1A1 P00352 4/20 0.35
▸ HPGD P15428 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ XBP1 P17861 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ TLR9 Q9NR96 1/20 0.35
▸ RPS6KB1 P23443 1/20 0.35
▸ KMT2A Q03164 2/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ NOD2 Q9HC29 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL209310 0.81 TSHR (0.50) HTTLMNATSHRMAPTKDM4E
SCHEMBL2401756 0.81 TSHR (0.41) HTTLMNATSHRMAPTKDM4E
SCHEMBL30225936 0.81 TSHR (0.50) HTTLMNATSHRMAPTKDM4E
SCHEMBL16475139 0.79 TSHR (0.38) TSHRMAPTPTGER4ALDH1A1KMT2A
SCHEMBL16260064 0.79 MAPT (0.42) HTTLMNAMAPTMITFSMN1; SMN2
SCHEMBL30648722 0.79 TSHR (0.38) TSHRMAPTPTGER4ALDH1A1KMT2A
SCHEMBL203339 0.79 LMNA (0.43) HTTLMNAMAPTKDM4EMITF
SCHEMBL2401652 0.75 CA1 (0.38) HTTLMNATSHRMAPTSMN1; SMN2
SCHEMBL24838570 0.75 PTGER4 (0.37) TSHRMAPTPTGER4ALDH1A1
SCHEMBL20129908 0.75 MAPT (0.38) HTTLMNATSHRMAPTPTGER4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025101780-A1 PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF OCTANT, INC. (US) 2025-05-15 — — WO disclosed
CN-114989164-B Substituted 1H-imidazo [4,5-b ] pyridin-2 (3H) -ones and uses thereof 詹森药业有限公司 2024-08-13 — — CN disclosed
US-20230338341-A1 SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-10-26 — — US disclosed
US-11759455-B2 Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2023-09-19 — — US disclosed
CN-111484480-B Polycyclic derivative inhibitor, preparation method and application thereof 上海翰森生物医药科技有限公司 2023-08-11 — — CN disclosed
EP-3523311-B1 SUBSTITUTED 1H-IMIDAZO[4,5-B]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-06-07 — — EP disclosed
US-11660303-B2 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity KANCERA AB (SE) 2023-05-30 — — US disclosed
US-20230000833-A1 SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-01-05 — — US disclosed
CN-114989164-A Substituted 1H-imidazo [4,5-b ] pyridin-2 (3H) -ones and uses thereof 詹森药业有限公司 2022-09-02 — — CN disclosed
CN-110062761-B Substituted 1H-imidazo [4,5-b ] pyridin-2 (3H) -ones and uses thereof 詹森药业有限公司 2022-05-13 — — CN disclosed
US-8088761-B2 Enzyme inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2012-01-03 — — US disclosed
US-8088761-B2 Enzyme inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2012-01-03 — — US disclosed
US-8088761-B2 Enzyme inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2012-01-03 — — US disclosed
US-20090247507-A1 Enzyme Inhibitors THE INSTITUTE OF CANCER RESEARCH (GB) 2009-10-01 — — US disclosed
US-20090247507-A1 Enzyme Inhibitors THE INSTITUTE OF CANCER RESEARCH (GB) 2009-10-01 — — US disclosed
US-20090247507-A1 Enzyme Inhibitors THE INSTITUTE OF CANCER RESEARCH (GB) 2009-10-01 — — US disclosed
WO-2009001021-A1 IMIDAZOPYRIDINE DERIVATIVES USEFUL AS ENZYME INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE AND AUTOIMMUNE DISEASES CHROMA THERAPEUTICS LTD. (GB) 2008-12-31 — — WO disclosed
EP-1963315-A2 ENZYME INHIBITORS The Institute of Cancer Research (GB) 2008-09-03 — — EP disclosed
WO-2007072017-A2 ENZYME INHIBITORS THE INSTITUTE OF CANCER RESEARCH (GB) 2007-06-28 — — WO disclosed
WO-2007072017-A2 ENZYME INHIBITORS THE INSTITUTE OF CANCER RESEARCH (GB) 2007-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230000833-A1 SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS GRIN2B, GRIN2A, GRIN2C HTT 507/4885LMNA 2730/4885TSHR 745/4885
US-20090247507-A1 Enzyme Inhibitors AURKC, AURKB, AURKA HTT 2611/4885LMNA 2674/4885TSHR 2859/4885
US-11759455-B2 Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators GRIN2B, GRIN2A, GRIN2C HTT 507/4885LMNA 2730/4885TSHR 745/4885
US-11660303-B2 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity ROR1, RORB, RORA HTT 4843/4885LMNA 3856/4885TSHR 1024/4885
US-20230338341-A1 SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS GRIN2B, GRIN2A, GRIN2C HTT 507/4885LMNA 2730/4885TSHR 745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.